Key Developments: Pfizer Ltd (PFIZ.NS)
1,044.20INR
23 May 2013
Rs-11.70 (-1.11%)
Rs1,063.15
Rs1,056.40
Rs1,066.45
Rs1,030.00
3,739
4,588
Rs1,399.45
Rs995.00
Latest Key Developments (Source: Significant Developments)
Pfizer Ltd Recommends Normal Dividend And Special Dividend
Pfizer Ltd announced that the Board of Directors of the Company at its meeting held on May 14, 2013, inter alia, has recommended a normal dividend of INR12.50 per Equity share of INR10 each (125%) and special dividend of INR20 per Equity share of INR10 each (200%) on account of sale of animal health business aggregating to a total dividend of INR32.50 per Equity share of INR10 each (325%) for the year ended March 31, 2013, The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on September 12, 2013. Full Article
Pfizer Ltd Announces Sale Of Its Wholly Owned Subsidiary Pfizer Animal Pharma Private Limited To Pfizer Animal Health India Limited
Pfizer Ltd announced that the Board of Directors of the Company at its meeting held on November 08, 2012, has approved, subject to receipt of prior regulatory approvals, the sale of its wholly owned subsidiary Pfizer Animal Pharma Private Limited to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of INR4.716 Billion (INR471.60 Crores). Full Article
Pfizer Ltd Loses Prempro Ruling, Must Pay $10.4 Million Court-The Economic Times
The Economic Times reported that Pfizer Ltd must pay $10.4 million in damages to a woman who blamed the Company's Prempro menopause drug for her breast cancer, an appeals court said. Jurors properly awarded Audrey Singleton , who sued Pfizer's Wyeth unit over Prempro, compensatory and punitive damages for the Company's marketing of the drug, the Pennsylvania Superior Court ruled on Saturday. Singleton's lawyers alleged that Wyeth hid the drug's health risks and a jury awarded her damages on those claims in 2010. She sued Wyeth, later acquired by Pfizer, in state court in Pennsylvania where the company has extensive operations. A Philadelphia jury awarded her $3.4 million in compensatory damages and $6 million in punitive damages in February 2010. The judge in the case later added almost $1 million in interest to the verdict. Full Article
Pfizer Ltd Appoints Mr. Aijaz Tobaccowalla As Managing Director
Pfizer Ltd announced that the Board of Directors of the Company at its meeting held on June 28, 2012, has accepted the resignation of Mr. Kewal Handa as the Director and Managing Director of the Company with effect from the end of day on August 15, 2012, Mr. Kewal Handa would continue as an employee of the Company until his retirement from the Company that is August 31, 2012. The Board of Directors at their meeting held on June 28, 2012 also appointed Mr. Aijaz Tobaccowalla as the Managing Director of the Company with effect from August 16, 2012 subject to approval of shareholders and Central Government. Full Article
Pfizer Ltd. Announces Retirement Of Mr. Kewal Handa As Managing Director
Pfizer Ltd. announced that Kewal Handa, Managing Director, pfizer Limited has decided to retire in August 2012 after two decades with Pfizer. Full Article
Pfizer Ltd. Completes Sale Of Animal Health Business To Wholly Owned subsidiary, Pfizer Animal Pharma Private Limited
Pfizer Ltd. announced that it has completed the sale of its animal health business to its wholly owned subsidiary, Pfizer Animal Pharma Private Limited. Transaction of the sale of the Company's animal health business to Pfizer Animal Pharma Private Limited has been closed and completed on April 3, 2012, for a consideration amount of INR440,00,00,000, subject to any adjustments as determined under the Business Transfer Agreement dated February 20, 2012, between the Company and Pfizer Animal Pharma Private Limited. Full Article
Pfizer Ltd. To Spin-off Animal Healthcare Business-Reuters
Reuters reported that Pfizer Ltd.'s Board has approved the sale of its animal healthcare business to its fully-owned unit for INR4.4 billion ($89.7 million). The unit will pay the amount either in cash or by issue of shares to the parent firm Pfizer Ltd. Full Article
Pfizer Ltd. Announces FDA Acceptance Of New Drug Application For Bosutinib
Pfizer Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistant or intolerant to imatinib as well as patients who were previously treated with dasatinib or nilotinib. There are no approved therapies available for CML patients after second-line treatment with dasatinib or nilotinib. Full Article
Pfizer Ltd. And Eisai Europe Ltd Announces New Study Shows Evidence Of Lower Rate Of Hippocampal Shrinkage In Alzheimer’s Disease Patients Treated With Aricept
Pfizer Ltd. and Eisai Europe Ltd announced the results from a new study conducted in France demonstrating Aricept (donepezil hydrochloride) 10mg significantly reduced the rate of hippocampal atrophy (reduction in volume) in patients with an amnestic syndrome at an early phase of Alzheimer's disease. The multi-centre, double-blind, randomised, placebo-controlled study was conducted to assess the effect of donepezil on the rate of hippocampal atrophy over one year in patients presenting an amnestic syndrome at a mild cognitive impairment (MCI) stage of the disease. A total of 216 patients were randomised to receive donepezil 10 mg daily or placebo. The study was conducted outside the licensed indication for donepezil in the European Union. Aricept is licensed for the symptomatic treatment of mild to moderately severe Alzheimer's dementia in Europe. The adverse events reported were consistent with the known safety profile of donepezil. The most commonly reported adverse events in this study were headaches, nightmares, cramps, nausea and diarrhea. Patients in the donepezil group exhibited a 45% lower rate of hippocampal atrophy than those in the placebo group after one year. There was no difference between the donepezil and placebo groups on any of the cognitive measures included in the study. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
